🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Frank Harrell Another reason to embrace longitudinal ordinal models! onlinelibrary.wiley.com/doi/10.1002/si…

Tony Felefly Only way to get a publication in this tier journal is to publish something anti-radiation

sciencedirect.com/science/articl…

Radiation therapy vs surgery outcomes in high-risk localized #ProstateCancer patients. SOUMYAJIT ROY RUSH Cancer Center joins Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss his systematic analysis of two major trials—CALGB 90203 (PUNCH) and RTOG 0521—to address the ongoing debate about

Tony Felefly 😃👍

Neither surgery nor SBRT is inert. Yet, chest wall pain after surgery is much more severe. Complicating matters, patients undergoing surgery often can't get off the opioids they need to tolerate the pain during the recovery period. You can learn more about CW pain management

Tony Felefly Biniam Kidane Ralph Weichselbaum Brendon Stiles Ankit Mangla, MD JeeSuk Chang Shankar Siva nasser altorki Alex Louie MD, PhD Jonathan Spicer MD PhD Ben Slotman Matthias Guckenberger Gerry Hanna CTSurgSocMedNetwork Jill Feldman LUNGevity Foundation x.com/DrewMoghanaki/…

Tony Felefly Alan Reyes-M.D Memorial Sloan Kettering Cancer Center Weill Cornell Medicine Chris Barbieri Jim Hu Elai Davicioni Dr. Jones Nauseef Cora Sternberg Scott Tagawa Ari E. Marciscano, MD European Urology Oncology Radbio calc and rationale below. Likely phase 3 dose for 20 fx should be 50-52.5. pubmed.ncbi.nlm.nih.gov/37608258/

John Christodouleas Neil Desai Vedang Murthy Sean Collins Prostate SBRT @ USF Health Priyamvada Maitre Tony Felefly Chad Tang, MD Jeff Ryckman Danny Vesprini Abhishek Solanki Tyler Seibert MD PhD Alejandro (Ale) Berlin Shahed Badiyan Elisha Fredman MD Agree that PTVs can be reduced but also important to re-think our traditional CTVs. See FROGG and PERYTON below. thegreenjournal.com/article/S0167-… sciencedirect.com/science/articl…

Danny Vesprini Vedang Murthy Abhishek Solanki John Christodouleas Neil Desai Sean Collins Prostate SBRT @ USF Health Priyamvada Maitre Tony Felefly Chad Tang, MD Jeff Ryckman Tyler Seibert MD PhD Alejandro (Ale) Berlin Shahed Badiyan Elisha Fredman MD Three questions come up for prostate bed (at least for me). 1. Is SBRT safe long-term (let's say 6.5 Gy x 5)? 2. If 5 Gy x 5 enough for microscopic disease in the nodes, why is it not enough for the bed? 3. Why treat the bed at all and can come back if local only recurrence since

Tony Felefly Danny Vesprini Vedang Murthy Abhishek Solanki John Christodouleas Neil Desai Sean Collins Prostate SBRT @ USF Health Priyamvada Maitre Chad Tang, MD Jeff Ryckman Tyler Seibert MD PhD Alejandro (Ale) Berlin Shahed Badiyan Elisha Fredman MD 1. Phase 3 trials in development (along with long term follow up ongoing from phase 2 trials). 2. No, not aware 3. Tagging Neil Desai on this one.

Thrilled and Grateful. Our review on metastasis-directed therapy in oligometastatic prostate cancer is now out in Seminars in Radiation Oncology. Thank you so much Vedang Murthy Piet Ost for your guidance and belief! Full text authors.elsevier.com/c/1lFrI3lXQoc1…

🚨 Just out in NEJM: #KEYNOTE689 💉🧠 Periop #pembrolizumab (neoadj + adj) + surgery + RT/CRT improves EFS in resectable LA-#HNSCC. First +ve phase 3 in this space! 🔥 🔹 EFS @ 3 yrs CPS ≥10: 59.8% vs 45.9% CPS ≥1: 58.2% vs 44.9% All pts: 57.6% vs 46.4% 📉 HR ~0.66–0.73 🧪 MPR: